Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by Bank of America from $8.00 to $11.00 in a research note released on Thursday morning, Stock Target Advisor reports. The firm currently has an underperform rating on the stock.

Other analysts have also issued reports about the stock. ValuEngine lowered shares of Teva Pharmaceutical Industries from a strong-buy rating to a buy rating in a research report on Tuesday, December 3rd. Gabelli upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a research report on Wednesday, October 16th. Cfra increased their price target on shares of Teva Pharmaceutical Industries from $11.00 to $13.00 and gave the company a hold rating in a research report on Wednesday. Cantor Fitzgerald increased their price target on shares of Teva Pharmaceutical Industries from $9.00 to $15.00 and gave the company a neutral rating in a research report on Wednesday. Finally, Wells Fargo & Co increased their price target on shares of Teva Pharmaceutical Industries from $8.00 to $10.00 and gave the company an equal weight rating in a research report on Wednesday, January 22nd. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $11.71.

Shares of TEVA stock traded down $0.35 during trading hours on Thursday, hitting $12.22. The company’s stock had a trading volume of 32,752,861 shares, compared to its average volume of 20,229,391. The business has a fifty day moving average of $10.37 and a 200-day moving average of $8.73. The stock has a market cap of $13.49 billion, a price-to-earnings ratio of -3.16, a P/E/G ratio of 1.24 and a beta of 1.84. Teva Pharmaceutical Industries has a twelve month low of $6.07 and a twelve month high of $18.08. The company has a current ratio of 0.89, a quick ratio of 0.56 and a debt-to-equity ratio of 1.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.61 by $0.01. The business had revenue of $4.47 billion for the quarter, compared to analyst estimates of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The company’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries will post 2.27 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, EVP Brendan P. O’grady sold 4,799 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, February 10th. The shares were sold at an average price of $12.27, for a total value of $58,883.73. Following the transaction, the executive vice president now owns 18,255 shares in the company, valued at approximately $223,988.85. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Hafrun Fridriksdottir sold 4,310 shares of Teva Pharmaceutical Industries stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.49, for a total transaction of $45,211.90. Following the completion of the transaction, the vice president now owns 24,883 shares in the company, valued at approximately $261,022.67. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,647 shares of company stock worth $257,561. 0.49% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Covenant Multifamily Offices LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Parkside Financial Bank & Trust raised its stake in shares of Teva Pharmaceutical Industries by 400.0% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,500 shares of the company’s stock valued at $25,000 after acquiring an additional 2,000 shares during the period. AdvisorNet Financial Inc raised its stake in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after acquiring an additional 1,525 shares during the period. Motco purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $28,000. Finally, Coastal Investment Advisors Inc. raised its stake in shares of Teva Pharmaceutical Industries by 90.4% in the 4th quarter. Coastal Investment Advisors Inc. now owns 4,002 shares of the company’s stock valued at $41,000 after acquiring an additional 1,900 shares during the period. Institutional investors own 53.73% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Do You Need a Fiduciary?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.